The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

Emory University

The United States of America As Represented by the Secretary of

The United States of America

University of Pennsylvania

US Government As Represented by the Secretary of the Army

University of Florida Research Foundation Inc

The State University of New York

The Salk Institute for Biological Studies

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

The Government of the United States of America

National Institute of Allergy and Infectious Diseases (niaid)

The Government of the United States of America, As Represented by the Secretary, Department of the Army

Bernard Moss

Patricia L Earl

Linda S Wyatt

Michael Mackett

Thomas R Fuerst

Robert H Purcell

Suzanne U Emerson

Harriet L Robinson

Zhaochun Chen

Ira H Pastan

Tamio Mizukami

Edward A Berger

Geoffrey L Smith

Girish J Kotwal

Frank J Gonzalez

Christopher C Broder

Harry V Gelboin

Gary H Cohen

Vijay K Chaudhary

David Fitzgerald

Robert W Doms

J Andrea McCart

David L Bartlett

Narayana Battula

Orna Elroy-Stein

John Charles Whitbeck

Lydia Aldaz-Carroll

Shlomo Lustig

Christiana Fogg

Sekhar Chakrabarti

Patricia Earl

Geoffrey Paul Smith

Jay A Berzofsky

Thomas M Folks

David J FitzGerald

Ted M Ross

David C Kaslow

F William Studier

Roselyn J Eisenberg

Rama Rao Amara

Ronald N Germain

Gene M Shearer

Vijay Kumar Chaudhary

Joseph J Esposito

Parker A Small, Jr

Mario S Clerici

Salvatore T Butera

James Smith

Anne Hosmalin

Thomas C VanCott

Bradley Stephen Bender

Arban Domi

Leigh Anne Eller

Matthew Edward Harris

Dennis Ellenberger

Stuart Isaacs

Roselyn J Eisenbert

Kathleen Brechling

Charles D Pendleton

Edward G Niles

Catherine Ann Meitin

Michael J Merchlinsky

John K Rose

Tilahun Yilma

Jian Hua

Rick Arthur Bright

James M Smith

Thomas Vancott

J Andrea Mccart

Christina Fogg

Lydia Aldaz-Carrol

Expression vectors ideal for use in vaccinating individuals against disease based on vaccinia virus and other chordopoxviruses having high expression of recombinant genes and low expression of vector genes in target animals, and low expression of recombinant genes and high expression of vector genes in cells used for propagation.

Virus-based expression vectors and uses thereof

The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.

Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites

The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Monoclonal antibodies against orthopoxviruses

The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).

Compositions and methods for generating an immune response

Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes

Monoclonal antibodies against Orthopoxviruses

The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

MVA expressing modified HIV envelope, gag, and pol genes

A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.

Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell

The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.

Compositions, methods and kits relating to poxvirus subunit vaccines

Growing community of inventors

Bethesda, MD, United States of America

Bernard Moss